Rani Therapeutics to Present Preclinical Data on Oral Delivery of Semaglutide via the RaniPill® Capsule at ObesityWeek® 2025

Stock Information for Rani Therapeutics Holdings Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Rani Therapeutics Holdings Inc.

Rani Therapeutics to Participate in the Evercore Healthcare Conference
Rani Therapeutics Reports Third Quarter 2025 Financial Results; Provides Corporate Update
Rani Therapeutics Announces the Appointments of Abe Bassan and Vasudev Bailey, Ph.D. to Board of Directors
Rani Therapeutics Announces Closing of Oversubscribed $60.3 Million Private Placement Priced At-the-Market under Nasdaq Rules
Rani Therapeutics Announces Oversubscribed $60.3 Million Private Placement Priced At-the-Market under Nasdaq Rules
Rani Therapeutics Announces up to $1.085 Billion Collaboration with Chugai Pharmaceutical Co. for Multiple High-Value Therapeutics Including Rare Disease and Immunology Programs and Announces Concurrent Oversubscribed $60.3 Million Financing
Rani Therapeutics Reports Second Quarter 2025 Financial Results; Provides Corporate Update
Rani Therapeutics Holdings, Inc. Announces Pricing of $3.0 Million Registered Direct Offering

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.